Caraco settles with Forest Labs

DETROIT Generic drug maker Caraco Pharmaceutical Labs has announced a settlement agreement with Forest Labs in litigation over an antidepressant.

Caraco said it would purchase several products from Forest’s Inwood business as part of the settlement, concerning the drug Lexapro (escitalopram oxalate). The asset purchase agreement settles litigation over an approval application that Caraco filed with the Food and Drug Administration to market a generic version of Lexapro.

Under the agreement, Forest has already reimbursed Caraco for a portion of its legal fees and will also license some of its patents for Lexapro to the company.